Abstract: HJ Science, a China-based clinical-stage biotech company, has passed the hearing for a Hong Kong Chapter 18A listing. CITIC Securities is the sole sponsor. In this note, we look at the company's core products HJ787, HJ178, and HJ891, and key product HJ197. We also look at the company's business development, pre-IPO investors, and management team.
Interested in the full report? Get in touch with our team.